Contraline

Contraline develops male contraceptive solutions, including an investigational drug in the form of a daily topical gel and an investigational implant.

Health and bioLAUNCH Accelerator

Latest funding

$92.5M Series B+ · June 2, 2026

Led by Biotechnology Value Fund · Source: fundraisingfox.com

Total raised: $105.45M across 3 sourced rounds

All 3 rounds ↓

Website: contraline.com.

X: @contraline · 636 followers.

LinkedIn: contraline.

Category: Health and bio.

Sectors: Biotechnology, Health Care, Medical, Men's.

Stage: Series B+.

Based in: Charlottesville, United States.

Founded: 2015.

Total raised: $105.45M in 3 sourced rounds.

Last round: Jun 2, 2026 · 166 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Sep 29, 2026.

Signals

X account@contraline · created Mar 27, 2016 (10 years old) · 636 followers

Website registeredJul 31, 2015 (11 years old)

About Contraline

These products are designed to provide effective, safe, and reversible contraceptive options for men and couples worldwide. The company operates within the reproductive health and urology space.

TIMELINE · MONEY RAISED

Contraline | 622 days from website to first raise on record

@contraline·Raised $105M in 3 sourced rounds·2 signals before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

Date	Round	Amount	Lead	Source
Jun 2, 2026	Series B+	$92.5M	BBiotechnology Value Fund	fundraisingfox.com
Oct 26, 2021	Series A	$10.7M	MMBX Capital	Femtech Insider
Apr 13, 2017	Seed	$2.25M	FFounders Fund	contraline.com

Timeline

March 27, 2016
X account created
July 31, 2015
Website created

Founders and team

KE
Kevin Eisenfrats Co-Founder and CEO

@kfrats · LinkedIn · source: foundertrace.com
JH
John Herr Founder
AP
Alex Pastuszak Chief Medical Officer
YT
Yelena Tropsha Chief Technology Officer

Investors

Companies like Contraline

AAvisi Technologies$10.7M Series A · Feb 2026
AAfrocenchixSeed · Sep 2021
FF2G$100M Series B+ · Sep 2024
CCelea Therapeutics$180M Series A · Jul 2026
TTopicalsSeries A · May 2026
BBright UroSeries A · Nov 2024

Other companies backed by Biotechnology Value Fund

DDren Bio$350M Series B+ · Oct 2026
CCrossbow Therapeutics$77M Series B+ · Mar 2026
TThird Arc Bio$52M Series A · Feb 2026
MMerida Biosciences$120M Series A · May 2025
AAlpha-9 Oncology$175M Series B+ · Oct 2024
AAltruBio$225M Series B+ · May 2024

Biotechnology Value Fund portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/contraline (get a free API key).